Navigation Links
Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug
Date:3/20/2012

gs, many of which have significant side effects. The potential market for XEN-D0103 is significant with one in four adults over the age of 40 developing AF in their lifetimes and approximately three million patients suffering atrial-fibrillation-related strokes each year. We are now preparing for the initiation of phase 2 efficacy trial of XEN-D0103 in patients with atrial fibrillation".

XEN-D0103 is the lead product of Xention's portfolio of atrial fibrillation drugs. In addition to targeting Kv1.5, Xention is also conducting research on inhibition of the acetylcholine-activated potassium channel IKACh (Kir3.1/3.4) and highly potent and selective IKACh antagonists are currently under evaluation in preclinical models. The ion channels Kv1.5 and IKACh represent two of the most exciting targets for novel atrial fibrillation therapies, and Xention is at the forefront in developing effective drug modulators of these channels.

About Atrial Fibrillation:

Atrial Fibrillation (AF) is the most common sustained cardiac rhythm disturbance, occurring in between 1 and 2 per cent of the general population but increasing rapidly with age.  It is estimated that over six million Europeans suffer from this arrhythmia and its prevalence is calculated to increase by at least 2.5 fold in the next 50 years as the population ages.  AF confers a five-fold increased risk of stroke and one in five of all strokes are attributable to AF.  The ischemic strokes seen in association with the arrhythmia are often fatal, and those that survive are often left crippled by their stroke and likely to suffer recurrent strokes.  Around one per cent of the healthcare budget of Western European and North American countries is spent on the management of AF.  Thus this disease presents a rapidly growing social, medical and public health problem in need of urgent solution.

Notes to Editors

About Xention:

Xention Ltd is a leading d
'/>"/>

SOURCE Xention
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GenVec Reports Fourth Quarter and 2011 Year-End Financial Results
2. EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results
3. Phalanx Biotech Group Reports Robust Revenue Growth in 2011
4. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
5. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
6. Gen-Probe Reports Financial Results for the Fourth Quarter of 2011
7. Neuland Labs Reports Third Quarter Fiscal Year 2012 Financial Results
8. Cepheid Reports Fourth Quarter and Full Year 2011 Results
9. Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M
10. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
11. Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... PALO ALTO, Calif. , Jan. 22. 2015  Varian Medical ... equipment and software, has been honored for its commitment to ... most sustainable companies. Varian is the highest ranked healthcare equipment ... ranking, announced today during the World Economic Forum at ...
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... Calif., March 12 ,Exelixis, Inc. (Nasdaq: EXEL ) ... executive officer of Exelixis, will present at the,Cowen and ... / 1:00 p.m.,PT on Monday, March 17, 2008. Dr. ... corporate strategy., The presentation will be webcast and ...
... DIEGO, March 12 Biomatrica, the leader in ... a reagent that enhances PCR and RT-PCR performance ... amplification of genomic,DNA or RNA templates., PCRboost ... that are,traditionally difficult to amplify and present in ...
... 12 Oncolys BioPharma,Inc. (Tokyo, Japan) and Tacere ... they have entered into a strategic alliance and,license ... interference (RNAi)-based Hepatitis C virus (HCV) compound, TT-033,code-named ... the,strategic alliance entered into by Tacere and Oncolys ...
Cached Biology Technology:Biomatrica's PCRboost(TM) Enables 5-Fold Improvement in Amplification of Difficult Samples 2Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug 2Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug 3
(Date:1/22/2015)... Jan. 15, 2015  BellBrook Labs, a leader in ... the launch of a TR-FRET (time resolved Forster ... UDP Assay, a high throughput screening assay for ... will allow for sensitive detection of hundreds of ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small Cap ... report showed that planet-wide, transactions at merchants on the leading ... total number of credit, debit, and prepaid cards reached 6.54 ... victims of fraudulent card usage in 2012, and credit and ...
(Date:1/22/2015)... CHARLOTTE, N.C. , Jan. 22, 2015 Infinisource has ... introduction of the G2 model. The G2 sets a higher ... company,s iSolved human capital management solution. With plug-and-play installation, touch ... G2 time clock provides a robust time collection solution for ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Infinisource's NXG series sets new time clock standard 2
... Ridge Associated Universities (ORAU), a consortium of 98 Ph.D.-granting ... sciences in the University of Delaware,s College of Earth, ... Junior Faculty Enhancement Award. The competitive award, which ... from the faculty member,s university, is intended to enrich ...
... the National Oceanography Centre (NOC) joins forces with the ... Porcupine Abyssal Plain sustained observatory (PAP-SO), the longest multidisciplinary ... advance scientific understanding of the ocean and improve climate ... North Atlantic off the Irish continental margin, where the ...
... PITTSBURGH, May 25 A two-year, $12 million contract ... Transition (OTT) will jumpstart human trials of three innovative ... with healthy, functional tissues, announced officials of the University ... today at the Institute,s Second Annual Open Session, Soldiers ...
Cached Biology News:University of Delaware professor wins Powe Award from Oak Ridge Associated Universities 2University of Delaware professor wins Powe Award from Oak Ridge Associated Universities 3Met Office and NOC enhance ocean observatory 2Pitt gets $12 million DoD contract for regenerative medicine treatment trials 2
Request Info...
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
...
Biology Products: